Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

CRISPR Therapeutics down 20% after hours on IND hold for sickle cell candidate CTX001

Published 05/30/2018, 05:16 PM
Updated 05/30/2018, 05:16 PM
© Reuters.  CRISPR Therapeutics down 20% after hours on IND hold for sickle cell candidate CTX001
  • CRISPR Therapeutics (NASDAQ:CRSP) slumps 20% after hours on robust volume in response to its disclosure that the FDA has placed a clinical hold on its IND for sickle cell disease (SCD) gene therapy candidate CTX001. The suspension will be in effect pending the resolution of certain questions related to the application.
  • Once approved, a U.S.-based Phase 1/2 study in adult SCD patients will commence. A Phase 1/2 study in adults with transfusion-dependent beta-thalassemia should start in H2 in Europe.
  • The company is co-developing the therapy with collaboration partner Vertex Pharmaceuticals (NASDAQ:VRTX).
  • SCD-related tickers: (NASDAQ:GBT)(NASDAQ:BLUE)(NYSE:SNY)(NASDAQ:SGMO)(NASDAQ:IRWD)
  • Previously: CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene editing candidate for blood disorders (Dec. 12, 2017)
  • Now read: Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.